Navigation Links
Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

May 2007. These dossiers, including these data, are expected to be submitted to the U.S. Food and Drug Administration in 2008.

Phase II Study Design and Results

The study was a randomized, double-blind, parallel-group study conducted at 18 centers in the U.S. in 90 patients with RRMS. The study evaluated the effect of 40 mg of COPAXONE(R) (glatiramer acetate injection) given daily versus 20 mg of COPAXONE(R) on disease activity as measured by MRI and clinical relapses, as well as the safety and tolerability of the 40 mg dose over a period of 9 months. Patients that qualified for this study had clinically-definite MS, had experienced a relapse in the previous year, had at least one Gd-enhancing lesion at screening visit, and had a Kurtzke Expanded Disability Status Scale (EDSS) score of 0-5. Patients were randomized in equal numbers to receive either 40 mg or 20 mg of COPAXONE(R). All patients underwent an MRI at baseline, and then at months 3, 7, 8 and 9. Neurological examinations were performed at screening, baseline, and again at months 3, 6 and 9, and suspected on-trial relapses were confirmed at an unscheduled visit within 7 days.

COPAXONE(R) 40 mg showed a 38 percent greater reduction of inflammatory disease activity as measured by mean cumulative number of Gd-enhancing T1 MRI lesions versus COPAXONE(R) 20 mg (p=0.0898). The benefit of the 40 mg dose was observed in as soon as 3 months (p=0.005) through MRI measurement. When compared to baseline numbers, the risk of having MRI activity (Gd-enhancement) in the 40 mg group at months 7, 8 and 9 was reduced by 75 percent (p<0.0001), compared to 65 percent in patients receiving the 20 mg dose (p<0.0001).

Relapse rates were also lower in patients who received the 40 mg dose of COPAXONE(R), when compared to those who received 20 mg dose (0.34 versus 0.57, respectively). Patients on 40 mg dose of COPAXONE(R) experienced a reduced on-trial mean relapse rate of 77 percent when compared to the
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:8/27/2015)... 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ) ... the Morgan Stanley Global Healthcare Conference on September 16, ... invited to listen to the live discussion via the ... at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay ... the conclusion of the live event and accessible via ...
(Date:8/27/2015)... The nation,s newest Actos trial gets underway Thursday, August 27 ... courtroom.  Attorneys representing two southern Nevada ... after using the diabetes drug Actos. "Takeda Pharmaceuticals ... that their drug Actos caused an increased risk of bladder ... hold Takeda responsible it is appropriate to seek substantial punitive ...
(Date:8/27/2015)...  Mytrus, a technology and services company revolutionizing clinical trials, announced ... has received approval for use by Britain,s ... first time e-Consent technology will be used in a ... Mytrus was also the first electronic informed consent ... the U.S. Food and Drug Administration in 2011. It ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... , SAN DIEGO, Oct. 26 Horizon Therapeutics, ... an analysis from two pivotal Phase 3 trials ... HZT-501, a combination of ibuprofen with high-dose famotidine. ... risk factors for the development of non-steroidal anti-inflammatory ...
... Volcano Corporation (Nasdaq: VOLC ), a leader in ... and treatment of coronary and peripheral artery disease, today announced ... quarter and first nine months of fiscal 2009 on Thursday, ... to discuss its financial results and operating activities open to ...
Cached Medicine Technology:Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 2Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 3Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users 4Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2
(Date:8/27/2015)... ... August 27, 2015 , ... ... , scheduled for October 27-29, 2015 in San Jose, CA. The first ... primarily focus on the void that exists where battery development and energy storage ...
(Date:8/27/2015)... ... 2015 , ... More destinations and stores are becoming pet-friendly, making the family ... sharing some tips to help your whole family travel safely and comfortably. , According ... each year. Amica is sharing the following tips from the American Society for the ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... blending all in one machine with the Nutri Ninja® Auto-iQ Pro Complete and ... Auto-iQ™ Smooth Boost™ Technology that takes drink customization to a whole new level. ...
(Date:8/27/2015)... ... 2015 , ... King Kullen, America’s First Supermarket, is celebrating 85 years of ... 1930 and recognized by the Smithsonian Institute as America’s First Supermarket, King Kullen changed ... Cullen & Kennedy families have created a culture of caring while building their business. ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... development solutions for drugs, biologics and consumer health products, today announced that Ms. ... FlyPharma Conference, to be held at the Radisson Blu Edwardian Hotel, London Heathrow, ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:King Kullen Honors Their 85 Years of Success this August 2Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2
... NEW YORK, Jan. 29 MS -- Cold and ... adults and children each year, according to,the Centers for ... can lead,to complications, especially in children and the elderly. ... be given within two days,of the infection,s onset., ...
... OAK BROOK, Ill. A novel treatment for blood clots ... to a pilot study published in the February issue of ... with a fiber-binding thrombolytic agent effectively treats deep vein thrombosis ... , This treatment regimen is able to clear blood clots ...
... New reports released,today by the Kaiser Family Foundation,s Commission ... states in the past year and,a half to expand ... may be curtailed as a deteriorating economic climate and ... in the economy, the federal failure to reauthorize the ...
... 28 NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ... groups across the United States, today announced its,preliminary, ... 31,2007. Results are subject to completion of the ... Results, The company expects to report 2007 ...
... Reminding People to Properly Care for Both their Body ,Engine, and Vehicle ... ... 28 Jiffy Lube today announces its,first-ever, nationwide cause-related campaign to support ... help eradicate,heart disease. Throughout February and March, 1,823 Jiffy Lube service,centers, more ...
... researchers is the first to conduct a genome-wide study ... to DNA mutations, which are implicated in cancer and ... of biology Kateryna Makova, the group investigated the simultaneous ... the susceptibility to mutations of microsatellites -- variable-length sequences ...
Cached Medicine News:Health News:Flu and Fever Detection Facts for Dr. Mom 2Health News:Flu and Fever Detection Facts for Dr. Mom 3Health News:New therapy effectively treats deep vein thrombosis 2Health News:States Promoted Broader Coverage for Children in 2007, But Report That a Declining Economy Coupled With Lack of SCHIP Reauthorization and New Federal Rules Now Compromise Efforts to Reduce the Number of Uninsured 2Health News:States Promoted Broader Coverage for Children in 2007, But Report That a Declining Economy Coupled With Lack of SCHIP Reauthorization and New Federal Rules Now Compromise Efforts to Reduce the Number of Uninsured 3Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results 3Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 2Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 3Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 4Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 5Health News:Scientists explore factors contributing to DNA mutations 2Health News:Scientists explore factors contributing to DNA mutations 3Health News:Scientists explore factors contributing to DNA mutations 4
... Medpor Channel Implants, designed to ... the surgeon with an excellent ... wall and floor blowout defects. ... for placement of one or ...
The new Medpor Superior Lateral Orbital Rim is designed for subtle augmentation of the lateral and superior or orbital rims in patients who are hypoplasic in the superior-lateral aspect of the orbita...
The new Medpor Orbital Rim Onlay Implants are designed to support the lower eyelid and lateral canthus in patients who have inadequate support due to congenital variation or changes with aging....
... handle. Divides nucleus for phacoemulsification. Nuclear division ... hardness can be pre-chopped with pre-chop forceps ... fragments is rapid. Risk of rupturing posterior ... sound time and minimal movement of phaco ...
Medicine Products: